2023

Cancer Vaccine mRNA-4157 Improves Recurrence-Free Survival for Patients With High-Risk Melanoma

Adjuvant treatment with mRNA-4157 plus pembrolizumab led to a 65% reduction in the risk of distant metastasis or death compared with pembrolizumab alone, among patients with resected melanoma at high risk of recurrence, according to findings from the phase 2 KEYNOTE-942 trial (NCT03897881) that were presented at the 2023 ASCO Annual Meeting.

Read More
MRV News
Melanoma News
Archive
Menu